Chemistry World is reporting “A new international network that grew out of President Obama’s 2015 antibiotic initiative aims to rejuvenate the antibiotic pipeline over the next five years with the help of hundreds of millions of dollars. The public–private partnership allies four research hubs in the fight against antimicrobial resistance (AMR) with the goal of getting promising molecules into preclinical trials faster.”

“Numerous reports have noted the parlous state of the world’s drugs to treat infection, with bacteria resistant to the antibiotic of last resort discovered in China last year. This has led to fears routine surgery could become impossible and that easily treated infections could once more be killers.”

“‘CARB-X is open to anybody. What we want is to make sure great ideas get progressed through to clinical development,’ says Peter Jackson, chairman of the AMR Centre, a public–private initiative based in Alderley Park, Cheshire. ‘We are willing to take on more risk than traditional financial investors and less traditional approaches.’ The AMR Centre aims to provide $14 million to support CARB-X projects in year one and up to $100 million over five years.

The network is focused on antibacterial products more broadly, not just therapeutics. It is open to small molecules, antibodies, diagnostics, vaccines and other approaches such as virulence modifiers. Initially, CARB-X will focus on Gram-negative bacteria and unconventional approaches.”

Read the full story on